Skip to main content

Advertisement

SpringerLink
Log in

Safely Avoiding Surgery in Adult Neurogenic Bladder

  • Neurogenic Bladder (C Powell, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the literature regarding non-surgical management of adult patients with high-pressure neurogenic bladder.

Recent Findings

Established therapies that facilitate bladder storage and emptying include anticholinergic medications, intradetrusor onabotulinum toxin injection, and intermittent catheterization. Application of these strategies to patients with elevated detrusor leak point pressures has shown improvement in bladder compliance and preservation of renal function. New interventions in the algorithm of management of patients with poor bladder compliance, such as beta-3 agonists and sacral neuromodulation to facilitate bladder storage the use of alpha antagonists and intraurethral onabotulinum toxin to facilitate bladder emptying are developing.

Summary

A multimodal approach to adult patients with high-pressure neurogenic bladder which includes intermittent catheterization, pharmacologic therapy, and intravesical onabotulinumtoxin injection has been associated with improved bladder compliance and preservation of renal function. Augmentation cystoplasty may be reserved for refractory cases. Data is emerging regarding new interventions that can facilitate bladder storage and emptying.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Wein A, Dmochowski RR. Neuromuscular dysfunction of the lower urinary tract. In: Wein A, Kavoussi LR, Partin AW, Peters C, editors. Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 1793.

    Google Scholar 

  2. • Blok B, Pannek J, Castro Diaz D, del Popolo G, Groen J, Gross T et al. European Association of Urology Guidelines on Neuro-Urology. 2017. https://uroweb.org/guideline/neuro-urology/. Accessed 12 Dec 2017. Comprehensive and evidence-based guidance for urologists.

  3. Nitti VW, Brucker BM. Urodynamic and video-urodynamic evaluation of the lower urinary tract. In: Wein A, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. Philadelphia: Elsevier; 2017. p. 1726.

    Google Scholar 

  4. Incontinence. 5th International Consultation on Incontinence. 5th ed. Paris: ICUD-EAU; 2013.

    Google Scholar 

  5. McGuire EJ. Urodynamics of the neurogenic bladder. Urol Clin N Am. 2010;37(4):507–16. https://doi.org/10.1016/j.ucl.2010.06.002.

    Article  Google Scholar 

  6. Shreck E, Gioia K, Lucioni A. Indications for augmentation cystoplasty in the era of onabotulinumtoxinA. Curr Urol Rep. 2016;17(4):27. https://doi.org/10.1007/s11934-016-0585-3.

    Article  PubMed  Google Scholar 

  7. Creevy CD. The management of neurogenic vesical dysfunction. Am Pract Dig Treat. 1948;3(2):71–4.

  8. Jameson RM. Surgical management of the neurogenic bladder and its complications. Br J Clin Pract. 1969;23(9):359–63.

    PubMed  CAS  Google Scholar 

  9. Wein AJ, Raezer DM, Benson GS. Management of neurogenic bladder dysfunction in the adult. Urology. 1976;8(5):432–43.

    Article  PubMed  CAS  Google Scholar 

  10. Lapides J, Diokno AC, Silber SM, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 2002;167(4):1584–6. https://doi.org/10.1016/S0022-5347(05)65158-0.

    Article  PubMed  Google Scholar 

  11. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205–9.

    Article  PubMed  CAS  Google Scholar 

  12. Dray EV, Cameron AP. Identifying patients with high-risk neurogenic bladder. Urol Clin. 44(3):441–52. https://doi.org/10.1016/j.ucl.2017.04.010.

  13. Ghoniem GM, Bloom DA, McGuire EJ, Stewart KL. Bladder compliance in meningomyelocele children. J Urol. 1989;141(6):1404–6.

    Article  PubMed  CAS  Google Scholar 

  14. McGuire EJ. Bladder compliance. J Urol. 1994;151(4):965–6.

    Article  PubMed  CAS  Google Scholar 

  15. National Spinal Cord Injury Statistical Center, Facts and Figures at a Glance. University of Birmingham, Birmigmham Alabama. 2017. https://www.nscisc.uab.edu/Public/Facts and Figures - 2017.pdf. Accessed Feb 13 2018.

  16. • Ginsberg D. Surveillance and management of urologic complications after spinal cord injury. In: Elliott SP, Gomez R, editors. Urologic management of the spinal cord injured patient. Montreal: Societe Internationale d'Urologie; 2016. p. 87–146. An international review of literature with evidence-based recommendations for clinical practice.

    Google Scholar 

  17. Filler G, Lee M. Educational review: measurement of GFR in special populations. Pediatr Nephrol (Berlin, Germany). 2017; https://doi.org/10.1007/s00467-017-3852-8.

  18. Pham-Huy A, Leonard M, Lepage N, Halton J, Filler G. Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida. J Urol. 2003;169(6):2312–5. https://doi.org/10.1097/01.ju.0000060205.23406.13.

    Article  PubMed  CAS  Google Scholar 

  19. Dangle PP, Ayyash O, Kang A, Bates C, Fox J, Stephany H, et al. Cystatin C-calculated glomerular filtration rate—a marker of early renal dysfunction in patients with neuropathic bladder. Urology. 2017;100:213–7. https://doi.org/10.1016/j.urology.2016.08.011.

    Article  PubMed  Google Scholar 

  20. Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72. https://doi.org/10.1016/j.juro.2012.09.081.

    Article  PubMed  Google Scholar 

  21. Abrams P. Urodynamics. 3rd ed. London: Springer-Verlag; 2006.

    Google Scholar 

  22. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

    Article  PubMed  Google Scholar 

  23. Lane GI, Gor RA, Katorski J, Elliott SP. Clinical outcomes of non-surgical management of detrusor leak point pressures above 40 cm water in adults with congenital neurogenic bladder. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23535.

  24. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062–7. https://doi.org/10.1016/j.juro.2009.05.038.

    Article  PubMed  Google Scholar 

  25. Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104(9):1246–50. https://doi.org/10.1111/j.1464-410X.2009.08600.x.

    Article  PubMed  CAS  Google Scholar 

  26. Cameron AP. Non-surgical urologic management of neurogenic bladder after spinal cord injury. In: Elliott SP, Gomez R, editors. Urologic management of the spinal cord injured patient. Montreal: Societe Internationale d'Urologie; 2016. p. 147–204.

    Google Scholar 

  27. • Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62. https://doi.org/10.3978/j.issn.2223-4683.2015.12.07. Comprehensive review of medical management of neurogenic bladder.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective beta3-Adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–90. https://doi.org/10.1016/j.eururo.2017.12.022.

    Article  PubMed  CAS  Google Scholar 

  29. Krhut J, Borovicka V, Bilkova K, Sykora R, Mika D, Mokris J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23566.

  30. Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. LUTS. 2018; https://doi.org/10.1111/luts.12218.

  31. Zachariou A, Filiponi M, Baltogiannis D, Giannakis J, Dimitriadis F, Tsounapi P, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24(6):9107–13.

    PubMed  Google Scholar 

  32. Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2018; https://doi.org/10.1111/luts.12215.

  33. Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. https://doi.org/10.1038/sc.2015.195.

    Article  PubMed  CAS  Google Scholar 

  34. Baron M, Grise P, Cornu JN. How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol. 2016;5(2):195–203. https://doi.org/10.5527/wjn.v5.i2.195.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665. https://doi.org/10.1056/nejm200003023420918.

    Article  PubMed  CAS  Google Scholar 

  36. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. https://doi.org/10.1016/j.eururo.2011.07.002.

    Article  PubMed  CAS  Google Scholar 

  37. Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor Overactivity. J Urol. 2012;187(6):2131–9. https://doi.org/10.1016/j.juro.2012.01.125.

    Article  PubMed  CAS  Google Scholar 

  38. Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol. 2013;31(6):1469–74. https://doi.org/10.1007/s00345-012-0984-0.

    Article  PubMed  CAS  Google Scholar 

  39. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. https://doi.org/10.1097/01.ju.0000162035.73977.1c.

    Article  PubMed  CAS  Google Scholar 

  40. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35. https://doi.org/10.1016/j.juro.2011.02.004.

    Article  PubMed  CAS  Google Scholar 

  41. Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport(R) (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36(2):457–62. https://doi.org/10.1002/nau.22954.

    Article  PubMed  CAS  Google Scholar 

  42. • Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol. 2016;5(1):117–26. https://doi.org/10.3978/j.issn.2223-4683.2015.12.01. Contemporary review of literature regarding neuromodulation for neurogenic bladder.

    Article  PubMed  PubMed Central  Google Scholar 

  43. • Barboglio Romo PG, Gupta P. Peripheral and sacral neuromodulation in the treatment of neurogenic lower urinary tract dysfunction. Urol Clin. 44(3):453–61. https://doi.org/10.1016/j.ucl.2017.04.011. Up to date review of literature regarding neuromodulation for neurogenic bladder.

  44. Chartier-Kastler EJ, Denys P, Chancellor MB, Haertig A, Bussel B, Richard F. Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourol Urodyn. 2001;20(1):61–71.

    Article  PubMed  CAS  Google Scholar 

  45. Chaabane W, Guillotreau J, Castel-Lacanal E, Abu-Anz S, De Boissezon X, Malavaud B, et al. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn. 2011;30(4):547–50. https://doi.org/10.1002/nau.21009.

    Article  PubMed  Google Scholar 

  46. Wollner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40. https://doi.org/10.1038/sc.2015.124.

    Article  PubMed  CAS  Google Scholar 

  47. Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5. https://doi.org/10.1038/sc.2013.155.

    Article  PubMed  CAS  Google Scholar 

  48. de Seze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306–11. https://doi.org/10.1002/nau.20958.

    Article  PubMed  Google Scholar 

  49. Kabay S, Kabay SC, Yucel M, Ozden H, Yilmaz Z, Aras O, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964–8. https://doi.org/10.1002/nau.20733.

    Article  PubMed  Google Scholar 

  50. •• Wang HH, Lloyd JC, Wiener JS, Routh JC. Nationwide trends and variations in urological surgical interventions and renal outcome in patients with spina bifida. J Urol. 2016;195(4 Pt 2):1189–94. https://doi.org/10.1016/j.juro.2015.11.033. Temporal and geographic trends in urologic surgery in patients with spina bifida and their relationship to chronic renal insufficiency.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109(9):1280–93. https://doi.org/10.1111/j.1464-410X.2011.10650.x.

    Article  PubMed  Google Scholar 

  52. • Jaggi A, Drake M, Siddiqui E, Fatoye F. A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23581. Comparison of NICE, EAU and ICI guidelines on neurogenic bladder.

  53. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease. London: Royal College of Physicians (UK).National Clinical Guideline Centre.; 2012.

  54. Wang SC, McGuire EJ, Bloom DA. A bladder pressure management system for myelodysplasia—clinical outcome. J Urol. 1988;140(6):1499–502.

    Article  PubMed  CAS  Google Scholar 

  55. Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Libr. 2013; https://doi.org/10.1002/14651858.CD004375.pub4.

  56. Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184(1):213–7. https://doi.org/10.1016/j.juro.2010.03.008.

    Article  PubMed  Google Scholar 

  57. Lane GI, Downs TM, Soubra A, Rao A, Hemsley L, Laylan C, et al. Tolerability of repeat use of blue light cystoscopy with Hexaminolevulinate for patients with urothelial cell carcinoma. J Urol. 2017;197(3 Pt 1):596–601. https://doi.org/10.1016/j.juro.2016.09.076.

    Article  PubMed  Google Scholar 

  58. Levy ME, Elliott SP. Reconstructive techniques for creation of catheterizable channels: tunneled and nipple valve channels. Transl Androl Urol. 2016;5(1):136–44. https://doi.org/10.3978/j.issn.2223-4683.2016.01.04.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.

    Article  PubMed  CAS  Google Scholar 

  60. Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597–603. https://doi.org/10.1016/j.apmr.2011.11.020.

    Article  PubMed  Google Scholar 

  61. Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014(5):Cd004927. https://doi.org/10.1002/14651858.CD004927.pub4.

  62. Goldfarb RA, Pisansky A, Fleck J, Hoversten P, Cotter KJ, Katorski J, et al. Neurogenic lower urinary tract dysfunction in adults with cerebral palsy: outcomes following a conservative management approach. J Urol. 2016;195(4 Pt 1):1009–13. https://doi.org/10.1016/j.juro.2015.10.085.

    Article  PubMed  Google Scholar 

  63. Pakula AT, Van Naarden Braun K, Yeargin-Allsopp M. Cerebral palsy: classification and epidemiology. Phys Med Rehabil Clin N Am. 20(3):425–52. https://doi.org/10.1016/j.pmr.2009.06.001.

  64. Wecht JM, Bauman WA. Decentralized cardiovascular autonomic control and cognitive deficits in persons with spinal cord injury. J Spinal Cord Med. 2013;36(2):74–81. https://doi.org/10.1179/2045772312y.0000000056.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Stubberud J, Langenbahn D, Levine B, Stanghelle J, Schanke AK. Emotional health and coping in spina bifida after goal management training: a randomized controlled trial. Rehabil Psychol. 2015;60(1):1–16. https://doi.org/10.1037/rep0000018.

    Article  PubMed  Google Scholar 

  66. Pruitt DW, Tsai T. Common medical comorbidities associated with cerebral palsy. Phys Med Rehabil Clin N Am. 20(3):453–67. https://doi.org/10.1016/j.pmr.2009.06.002.

  67. Lopes MA, Lima ED. Continuous use of intermittent bladder catheterization—can social support contribute? Rev Lat Am Enfermagem. 2014;22(3):461–6.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Serres C. Shortage of home health workers forcing young Minneostans with disabilities into institutions. Star Trib. 2018;5:2018.

    Google Scholar 

  69. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23(2):207–18. https://doi.org/10.1037/0278-6133.23.2.207.

    Article  PubMed  Google Scholar 

  70. Krause JS, Carter RE. Risk of mortality after spinal cord injury: relationship with social support, education, and income. Spinal Cord. 2009;47(8):592–6. https://doi.org/10.1038/sc.2009.15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Muller R, Peter C, Cieza A, Geyh S. The role of social support and social skills in people with spinal cord injury—a systematic review of the literature. Spinal Cord. 2012;50(2):94–106. https://doi.org/10.1038/sc.2011.116.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Minnesota Urology Department, 420 Delaware Street SE, MMC 394, Minneapolis, MN, 55455, USA

    Giulia I. Lane & Sean P. Elliott

  2. Minneapolis V.A.M.C. Urology Section, Minneapolis, MN, USA

    Giulia I. Lane

Authors
  1. Giulia I. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean P. Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean P. Elliott.

Ethics declarations

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

This article is part of the Topical Collection on Neurogenic Bladder

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lane, G.I., Elliott, S.P. Safely Avoiding Surgery in Adult Neurogenic Bladder. Curr Bladder Dysfunct Rep 13, 169–177 (2018). https://doi.org/10.1007/s11884-018-0479-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-018-0479-y

Keywords

Search

Navigation